138 related articles for article (PubMed ID: 22287731)
21. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway.
Arafa el-SA; Zhu Q; Barakat BM; Wani G; Zhao Q; El-Mahdy MA; Wani AA
Cancer Res; 2009 Dec; 69(23):8910-7. PubMed ID: 19903849
[TBL] [Abstract][Full Text] [Related]
22. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.
Fujiwara M; Izuishi K; Sano T; Hossain MA; Kimura S; Masaki T; Suzuki Y
J Exp Clin Cancer Res; 2008 Nov; 27(1):76. PubMed ID: 19032736
[TBL] [Abstract][Full Text] [Related]
23. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
[TBL] [Abstract][Full Text] [Related]
24. Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
Schlosshauer PW; Li W; Lin KT; Chan JL; Wang LH
Gynecol Oncol; 2009 Sep; 114(3):516-22. PubMed ID: 19576622
[TBL] [Abstract][Full Text] [Related]
25. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
[TBL] [Abstract][Full Text] [Related]
26. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C
Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124
[TBL] [Abstract][Full Text] [Related]
27. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Shingu T; Yamada K; Hara N; Moritake K; Osago H; Terashima M; Uemura T; Yamasaki T; Tsuchiya M
Cancer Res; 2003 Jul; 63(14):4044-7. PubMed ID: 12874004
[TBL] [Abstract][Full Text] [Related]
28. [Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
Zhang XJ; Zhang L; Liu YP; Xu HM; Sun P; Song JG; Luo YH
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):181-6. PubMed ID: 23879997
[TBL] [Abstract][Full Text] [Related]
29. Wortmannin enhances cisplatin-induced apoptosis in human ovarian cancer cells in vitro.
Zhao JX; Liu H; Lv J; Yang XJ
Eur Rev Med Pharmacol Sci; 2014; 18(17):2428-34. PubMed ID: 25268086
[TBL] [Abstract][Full Text] [Related]
30. Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.
Correa RJ; Valdes YR; Peart TM; Fazio EN; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
Carcinogenesis; 2014 Sep; 35(9):1951-61. PubMed ID: 24562574
[TBL] [Abstract][Full Text] [Related]
31. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
[TBL] [Abstract][Full Text] [Related]
32. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells.
Wang Y; Kuramitsu Y; Baron B; Kitagawa T; Tokuda K; Akada J; Maehara SI; Maehara Y; Nakamura K
Int J Oncol; 2017 Feb; 50(2):606-612. PubMed ID: 28000865
[TBL] [Abstract][Full Text] [Related]
33. LY294002 enhances inhibitory effect of gemcitabine on proliferation of human pancreatic carcinoma PANC-1 cells.
Ke XY; Wang Y; Xie ZQ; Liu ZQ; Zhang CF; Zhao Q; Yang DL
J Huazhong Univ Sci Technolog Med Sci; 2013 Feb; 33(1):57-62. PubMed ID: 23392708
[TBL] [Abstract][Full Text] [Related]
34. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
[TBL] [Abstract][Full Text] [Related]
35. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
[TBL] [Abstract][Full Text] [Related]
36. The O-methylated isoflavone, formononetin, inhibits human ovarian cancer cell proliferation by sub G0/G1 cell phase arrest through PI3K/AKT and ERK1/2 inactivation.
Park S; Bazer FW; Lim W; Song G
J Cell Biochem; 2018 Sep; 119(9):7377-7387. PubMed ID: 29761845
[TBL] [Abstract][Full Text] [Related]
37. Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy.
Wang J; Liang D; Zhang XP; He CF; Cao L; Zhang SQ; Xiao X; Li SJ; Cao YX
Int J Oncol; 2021 Jan; 58(1):70-82. PubMed ID: 33367926
[TBL] [Abstract][Full Text] [Related]
38. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
39. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O
Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221
[TBL] [Abstract][Full Text] [Related]
40. Phenoxodiol enhances the antitumor activity of gemcitabine in gallbladder cancer through suppressing Akt/mTOR pathway.
Li Y; Huang X; Huang Z; Feng J
Cell Biochem Biophys; 2014 Nov; 70(2):1337-42. PubMed ID: 24902539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
